Sodium-dependent phosphate cotransporter (NaPi)

Sodium-dependent phosphate cotransporters are integral membrane proteins that facilitate the movement of inorganic phosphate into cells by coupling it with the downhill gradient of sodium ions. These transporters are primarily categorized into the SLC34 (NaPi-II) and SLC20 (PiT) families, with NaPi-IIa and NaPi-IIc handling renal reabsorption and NaPi-IIb managing intestinal absorption [UniProt: Q06495, O95436]. They play a fundamental role in maintaining systemic phosphate homeostasis, a process tightly regulated by hormones like parathyroid hormone and FGF23 [PMID: 17609305]. Dysregulation of these symporters is a hallmark of chronic kidney disease (CKD), where impaired excretion leads to hyperphosphatemia and subsequent cardiovascular complications. Although the provided name suggests they are not drug targets, they are in fact significant therapeutic targets; inhibitors such as nicotinamide and experimental pan-NaPi inhibitors (e.g., EOS789) are utilized or studied to manage phosphate burden in renal patients [PMID: 33158945]. Targeting these transporters provides a direct method to control mineral metabolism and mitigate the progression of secondary hyperparathyroidism and vascular calcification [PMID: 25612545].

Other names

Sodium-phosphate symporterSLC34 familySLC20 familyNaPi-IIPiTSodium-phosphate cotransporter

Inhibition of apical sodium-coupled phosphate transport in the renal proximal tubules or intestinal epithelium to decrease systemic phosphate levels by reducing reabsorption or absorption, respectively [PMID: 21847110].